Cedar Park Regional Medical Center’s Post

Eli Lilly Chair and CEO Dave Ricks has helped disrupt the healthcare industry with the company’s obesity drugs, but he hopes and predicts that the next decade of transformative medicines will focus on brain health. Dave notes how the science is much more tractable now for neurodegenerative conditions than it has been in the past, and how the world’s most valuable pharmaceutical company is investing in and prioritizing treatments for Parkinson’s, ALS, Alzheimer’s, and more. Listen to Dave's insights on advancing “the last frontier” of brain health, breakthroughs in diabetes and obesity drugs, and more on our recent #GoldmanSachsTalks: https://lnkd.in/eSg6tQaD

Changes, like the American Rescue Plan Act lowering insulin prices and the introduction of Humira biosimilars post-patent expiration, have decreased drug prices and rebates. This poses a challenge for pharmacy benefit managers (PBMs) to meet rebate guarantees, prompting them to introduce "rebate credit values" for switching to cheaper drugs. While simplifying financial evaluations, this method can mislead budget analyses by inflating drug costs and rebate projections. This discrepancy can harm employer-sponsored health plans that rely on accurate estimates for effective budget management. Lack of transparency and consistency in using rebate credit values may lead to inflated projections, complicating financial planning, and potentially increasing healthcare costs. #PharmacyBenefitManagers #HealthcareCosts #DrugPricing

Changes, like the American Rescue Plan Act lowering insulin prices and the introduction of Humira biosimilars post-patent expiration, have decreased drug prices and rebates. This poses a challenge for pharmacy benefit managers (PBMs) to meet rebate guarantees, prompting them to introduce "rebate credit values" for switching to cheaper drugs. While simplifying financial evaluations, this method can mislead budget analyses by inflating drug costs and rebate projections. This discrepancy can harm employer-sponsored health plans that rely on accurate estimates for effective budget management. Lack of transparency and consistency in using rebate credit values may lead to inflated projections, complicating financial planning, and potentially increasing healthcare costs. #PharmacyBenefitManagers #HealthcareCosts #DrugPricing

🏥 Community Health Systems to utilize 💊 Mark Cuban Cost Plus Drug Company, PBC 🔍 Mark Cuban Cost Plus Drug Co. is now serving as a wholesale drug distributor for all 71 hospitals affiliated with Community Health Systems (CHS)! 💊 Cost Plus Drugs launched with generic medications online with transparent and often inexpensive pricing, and this collaboration marks the first time they’re extending this offering to a large health system. 🏥 CHS hospitals will purchase 12 generic therapies through Cost Plus Drugs Marketplace (For Business), which is the name of their wholesale business. These generics cover a range of conditions, including infections, nausea, glaucoma, acid reflux, and hyponatremia. Mark Cuban Cost Plus Drug Company, PBC aims to make healthcare more affordable. By charging a 15% markup, they’re ensuring hospitals get access to medications without the usual price inflation. Plus, they have direct relationships with major generic manufacturers, streamlining the process. #digitalhealth #healthsystems #healthcareinnovation #healthcare #pharma #genericmeds

The Drug Discount Ecosystem Needs Clarity in 2024 and Beyond: Today’s guest post comes from Gavin Magaha, Senior Director of Value Delivery at Kalderos. Gavin discusses the problems manufacturers face in accessing and standardizing drug discount data. These data are necessary to avoid duplicate discounts and comply with regulatory requirements. To learn more about how the Inflation Reduction Act adds to challenges of drug discount programs, download Kalderos’ whitepaper: Operational Complexity and Evolving Challenges: What Drug Manufacturers Need to Know Now About Drug Discount Programs, the Inflation Reduction Act, and 340B. Read on for Gavin’s insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #lifesciences #financial

During a recent webinar we cohosted with the @Medical Review Institute of America, we discussed proven strategies for achieving a remarkable 15:1 ROI through their effective High-Cost Specialty Drug Reviews™ program. Whether you're new to managing high-cost specialty drugs or looking to enhance your existing processes, these insights are sure to empower you to make informed decisions. Reach out to [email protected] with any lingering questions, or watch the full webinar here if you missed it: https://lnkd.in/gm7aCfnM #SpecialtyDrugs #PopulationHealth #HealthcareSavings

The impacts are clear: #GenericMedicines 💊 make important economic contributions for people and healthcare systems around the world. For healthcare systems, generics have lower prices due to the elimination of the high costs associated with drug development. And the competition and savings from generics foster innovation, ultimately creating more solutions for patients and systems. For instance, in the United States, generic and biosimilar prescriptions account for 90% of prescriptions filled, yet only 17.5% of their prescription drug spending. (Association for Accessible Medicines) And for people, the impacts are even more clear: lower costs mean more patients can afford necessary medications, leading to better overall health outcomes 👴👵 Benefits like these are why we come together for one mission: #MakingAffordableMedicinesAvailableToAll

The Drug Discount Ecosystem Needs Clarity in 2024 and Beyond: Today’s guest post comes from Gavin Magaha, Senior Director of Value Delivery at Kalderos. Gavin discusses the problems manufacturers face in accessing and standardizing drug discount data. These data are necessary to avoid duplicate discounts and comply with regulatory requirements. To learn more about how the Inflation Reduction Act adds to challenges of drug discount programs, download Kalderos’ whitepaper: Operational Complexity and Evolving Challenges: What Drug Manufacturers Need to Know Now About Drug Discount Programs, the Inflation Reduction Act, and 340B. Read on for Gavin’s insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #lifesciences #financial

Last week, the Biosimilars Forum and its member companies met with lawmakers on Capitol Hill to thank them for their leadership on biosimilars and discuss the importance of increasing access to these lower-cost medicines. Biosimilars are a bipartisan solution to lower drug costs for millions of Americans, and the work being done by policymakers to increase uptake is imperative to unlocking their cost-savings potential. We look forward to our continued work with both sides of the aisle and the Administration to realize the promise of biosimilars. #biosimilars 

You may have seen "Drug Middlemen Push Patients to Pricier Medicines, House Probe Finds" in the Wall Street Journal. Pharmacy Benefit Managers (PBMs) are middlemen between company health plans and Pharma companies. As costs go up, so do their profits. 💲 On average, an employer's pharmacy expenditure is 25% of the total claims cost, with some as high as 50-60%. 💡 Join this webinar to learn more about the contributors driving higher costs and innovations to get a fair price at the pharmacy. The discussion will include: • Strategies to better manage pharmacy costs • Navigating and understanding the delicate balance between coverage and costs. • The future of the FDA drug pipeline This webinar is approved for 1 hour of SHRM credit Register now: https://bit.ly/4f4OU7z